Comparison Between Corticosteroid and Topical Steroids in the DRESS

Inclusion Criteria: * patient age ≥ 18 years * signing informed consent form * DRESS diagnosis with at least 4 criteria a, b, c, d 1. Skin rash occurring at least 10 days and not more than two months after continuous drug intake (or within less than 10 days in case of rechallenge) 2. Fever ≥ 38 ° at the time of examination or fever ≥ 38.5 ° peak in the last 72 hours (amendment 2 : ANSM + CPP : 08/04/14) 3. at least one visceral compatible : * lymphadenopathy on at least two different sites measuring at least 1 cm in diameter * transaminases \> 2 upper limit of normal (ULN) or alkaline phosphatise \> 3 ULN * lung involvement defined by hypoxemia (capillary oximetry ≤ 95%) and/or interstitial lung disease on chest radiography or scanner, in absence of other lung disease * myocarditis, pericarditis (ECG clinical suspicion and confirmed by echocardiography) * renal impairment defined as creatinine increase above the normal laboratory value associated with leucocyturia \> 1000 / mm3 or proteinuria, a Na / K ratio \>1 and Urine Cyto-bacteriology (EBCU) sterile in the absence of preexisting renal disease d) At least one of the following haematological abnormalities: * eosinophilia ≥ 0.7 g/l or \> 10 % absolute * lymphocytosis ≥ 5\*10\^9 /l * presence of atypical blood lymphocytes * Patient with moderate DRESS : defined by at least one reached as follows : * pulmonary: interstitial pneumonia with oxygen partial pressure in arterial blood (PaO2) 60-75 mmHg without dyspnoea at rest * Hepatic: transaminases ≥ 4 ULN and \< 15 ULN and/or PAL ≥5 ULN and V factor 50% (amendment 2 : ANSM + CPP : 08/04/14) * renal : * acute renal failure and organic sharp increase in the 48 hours preceding the inclusion of more of 26.4 micromol/l creatinine * and / or increase of 1.5 times the normal creatinine value * and / or decrease of oliguria of less than 0.5 ml/kg/h followed by a 6 hours * cord: pancytopenia (7≤Hb≤10 gr/dl and/or 50\<p\<100 G/L, 0.5\<PNN≤1.5G/l) * AND absence of cardiac, neurological or gastrointestinal (gut, pancreas) threatening * Drug withdrawal * Patient with health insurance (or entitled beneficiary) * Patient accepting the constraints of the test Exclusion Criteria: * uncontrolled sepsis * unability to discontinue the medication(s) due * known hypersensitivity to systemic or topical corticosteroids * hepatitis B or C known, (active HIV status known suppressed by amendment 5 : ANSM16/04/2015 and CPP 07/04/2015) * (Patient already treated by corticosteroid : * More than 48 hours * Less than 48 hours to following conditions : * Patients receiving more than 1 mg/kg/day of prednisone per os * Patients receiving methylprednisolone pulse up to 1mg/kg prednisone equivalent * (Patients receiving more than 30 grams per day level 3 topical steroid or more than 10 grams per day level 4 topical steroid --\> suppressed by amendment 3 : ANSM 28/05/14 CPP : 10/06/14) * (Patient undergoing immunosuppressive therapy for another disease suppressed by amendment 5 : ANSM16/04/2015 and CPP 07/04/2015) * Participation in another drug biomedical research * Primitive bacterial infections, fungal or parasitic * Severe rosacea cont-indicating the use of corticosteroid * Presence of at least one ulcerated lesion (more than 10cm2) * Severe dermatitis perioral cont-indicating the use of corticosteroid * Severe acne contra-indicating the use of a corticosteroid * Pregnant or nursing women